Marksans Pharma gets US FDA nod for Paricalcitol drug

Paricalcitol capsules is a synthetic Vitamin D analog

Marksans Pharma has received approval from the US health regulator for Paricalcitol capsules, used for treating hyper parathyroidism.

“US FDA has granted approval for an abbreviated new drug application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg,” Marksans Pharma said in a BSE filing.

Paricalcitol capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol capsules is a synthetic Vitamin D analog.

“Vitamin D is important for absorption of calcium from the stomach and for functioning of calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism,” the company said.

PTI